Drug Profile
DSP 6745
Alternative Names: DSP-6745Latest Information Update: 21 Nov 2022
Price :
$50
*
At a glance
- Originator Sumitomo Dainippon Pharma
- Developer Sumitomo Pharma
- Class Antiparkinsonians; Antipsychotics
- Mechanism of Action Serotonin 2A receptor antagonists; Serotonin 2C receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Psychotic disorders
Most Recent Events
- 21 Nov 2022 Discontinued - Phase-I for Psychotic disorders in USA (PO) (Sumitomo Pharma pipeline, November 2022)
- 24 May 2022 Phase I development in Psychotic disorders is ongoing in USA (PO) (Sumitomo Pharma pipeline, May 2022)
- 28 Apr 2022 No recent reports of development identified for phase-I development in Psychotic-disorders in USA (PO)